Category: Interviews

Dr. Brian Kennedy is a longevity heavyweight: a former President of the Buck Institute, currently a Distinguished Professor in the Department of Biochemistry and Physiology at the National University of Singapore, a co-editor of Aging Cell, and one of the researchers behind a recent study of alpha-ketoglutarate that resulted in winding back chronological age in...

At Ending Age-Related Diseases 2021, Elena Milova of Lifespan.io interviewed Tina Woods on the development of a longevity ecosystem, the importance of language, and the social aspects of extending lifespans. Script Elena: Greetings to the participants of Ending Age-Related Diseases 2021. This conference brings together thought leaders and researchers working on rejuvenation biotechnology with the...

At Ending Age-Related Diseases 2021, Elena Milova of Lifespan.io interviews Tim Maupin, an NYC-based filmmaker, about the way art can help change the way society views longevity research. Script Elena: Greetings to the participants of Ending Age-Related Diseases 2021. This conference brings together thought leaders and researchers working on rejuvenation biotechnology with the goal of...

At Ending Age-Related Diseases 2021, Elena Milova interviewed Dr. Jean Hébert on how the human brain can be restored to youthful function. Script Elena: Greetings to the participants of Ending Age-Related Diseases 2021. This conference brings together thought leaders and researchers working on rejuvenation biotechnology with the goal of extending healthy human life. The supposed...

Before founding Impetus Grants, a non-profit that aims to speed up longevity research by handing out money to scientists, minus the bureaucracy, Martin Borch Jensen did his doctorate in the Bohr lab at the NIA and his postdoc at the Buck Institute, and he received an NIH Pathway to Independence award that would have enabled...

Lorna Harries is a Professor of Molecular Genetics at the University of Exeter Medical School. She is also the CSO and R&D lead at SENISCA Ltd. Like many other companies, and as evidenced by the name, SENISCA targets senescent cells, albeit using an unusual mRNA-based approach. After Lorna gave a fascinating talk at our Ending...